Table 2.
Experimental runs, independent variables and measured responses of voriconazole ultradeformable elastosomes.
| Formulaa | Composition |
Y1: EE % | Y2: PS (nm) | Y3: ZP (mV) | Y4: PDI | ||
|---|---|---|---|---|---|---|---|
| X1: PC: EA ratio | X2: Hyaluronic acid % w/v | X3: PVA % | |||||
| E1 | 4.00 | 0.75 | 3.00 | 62.2 ± 0.7 | 431.6 ± 4.4 | −47.9 ± 4.8 | 0.316 ± 0.05 |
| E2 | 1.00 | 0.25 | 3.00 | 53.7 ± 2.7 | 310.8 ± 0.5 | −41.8 ± 1.1 | 0.293 ± 0.06 |
| E3 | 1.00 | 0.50 | 1.00 | 49.6 ± 2.6 | 333.7 ± 9.5 | −45.7 ± 4.1 | 0.329 ± 0.04 |
| E4 | 2.50 | 0.75 | 1.00 | 47.9 ± 1.2 | 435.2 ± 13.9 | −50.6 ± 1.3 | 0.367 ± 0.09 |
| E5b | 2.50 | 0.50 | 3.00 | 55.5 ± 1.8 | 363.6 ± 9.1 | −47.6 ± 0.5 | 0.315 ± 0.02 |
| E6 | 4.00 | 0.50 | 5.00 | 67.9 ± 0.8 | 371.5 ± 7.7 | −49.4 ± 1.9 | 0.341 ± 0.08 |
| E7 | 4.00 | 0.50 | 1.00 | 65.4 ± 1.2 | 418.7 ± 28.3 | −48.6 ± 3.9 | 0.303 ± 0.05 |
| E8b | 2.50 | 0.50 | 3.00 | 57.3 ± 5.5 | 357.3 ± 20.6 | −46.7 ± 5.3 | 0.298 ± 0.05 |
| E9 | 1.00 | 0.50 | 5.00 | 47.2 ± 1.7 | 321.6 ± 6.9 | −42.8 ± 1.3 | 0.313 ± 0.03 |
| E10 | 1.00 | 0.75 | 3.00 | 39.7 ± 2.4 | 342.3 ± 6.9 | −46.5 ± 0.2 | 0.425 ± 0.07 |
| E11 | 2.50 | 0.75 | 5.00 | 60.6 ± 0.1 | 427.3 ± 14.6 | −49.9 ± 2.8 | 0.384 ± 0.12 |
| E12b | 2.50 | 0.50 | 3.00 | 51.1 ± 9.9 | 352.3 ± 20.8 | −43.9 ± 6.2 | 0.346 ± 0.08 |
| E13 | 2.50 | 0.25 | 5.00 | 67.4 ± 1.0 | 345.3 ± 28.9 | −39.5 ± 1.2 | 0.193 ± 0.13 |
| E14 | 2.50 | 0.25 | 1.00 | 64.9 ± 2.1 | 347.5 ± 5.6 | −42.5 ± 0.9 | 0.197 ± 0.06 |
| E15 | 4.00 | 0.25 | 3.00 | 72.8 ± 0.3 | 375.5 ± 3.1 | −40.3 ± 0.5 | 0.231 ± 0.03 |
Presented values are the mean ± SD (n = 3).
PC: phosphatidyl choline; EA: edge activator; PVA: polyvinyl alcohol; EE%: entrapment efficiency percentage; PS: particle size; ZP: zeta potential; PDI: polydispersity index.
a
All formulae contained 40 mg VCZ and a total of 500 mg of PC + EA, in a volume of 10 ml. The drug content of formulae ranged from 95.3 to 102.7 %.
b
Center points.